Victory Capital Management Inc. reduced its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 1.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 130,573 shares of the specialty pharmaceutical company’s stock after selling 1,490 shares during the quarter. Victory Capital Management Inc. owned about 0.89% of KemPharm worth $522,000 at the end of the most recent reporting period.
Separately, C WorldWide Group Holding A S boosted its position in shares of KemPharm by 110.1% during the 2nd quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after acquiring an additional 200,000 shares during the last quarter. Institutional investors own 40.01% of the company’s stock.
Shares of KemPharm, Inc. (KMPH) opened at 3.80 on Tuesday. KemPharm, Inc. has a 12 month low of $2.45 and a 12 month high of $5.40. The company has a 50-day moving average price of $3.08 and a 200-day moving average price of $3.79. The company’s market capitalization is $55.70 million.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.19. On average, analysts forecast that KemPharm, Inc. will post ($2.72) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/19/victory-capital-management-inc-lowers-stake-in-kempharm-inc-kmph.html.
In related news, major shareholder Delaware Street Capital Master acquired 325,888 shares of the stock in a transaction on Thursday, September 14th. The shares were bought at an average price of $3.27 per share, with a total value of $1,065,653.76. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 334,888 shares of company stock worth $1,088,954 in the last three months. 22.80% of the stock is currently owned by corporate insiders.
KMPH has been the subject of a number of research reports. Roth Capital initiated coverage on KemPharm in a research report on Wednesday, June 28th. They set a “buy” rating and a $8.00 target price for the company. ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 1st. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Canaccord Genuity reiterated a “buy” rating and set a $7.00 target price on shares of KemPharm in a research report on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. set a $13.00 target price on KemPharm and gave the company a “buy” rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $8.10.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Want to see what other hedge funds are holding KMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KemPharm, Inc. (NASDAQ:KMPH).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.